报价延迟最少15分钟:2025/07/24 17:46 EDT
盘后时段
|
||||
|
0.7201 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.7367
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.60/-1.36
|
|
企业价值
14.14M
|
| 资产负债 |
|
每股账面净值
0.22
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/24 17:46 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM)analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously. |
